Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 58,810,206 | 50,842,378 | 42,784,390 | 40,275,703 | 21,630,486 | 214,343,163 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 58,810,206 | 50,842,378 | 42,784,390 | 40,275,703 | 21,630,486 | 214,343,163 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | 214,343,163 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 58,810,206 | 50,842,378 | 42,784,390 | 40,275,703 | 21,630,486 | 214,343,163 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 1,316,372 | 1,354,513 | 1,590,672 | 1,538,331 | 1,252,653 | 7,052,541 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 2,246,081 | 1,819,001 | 2,097,498 | 1,822,760 | 858,301 | 8,843,641 |
| 11 | Total support. Add lines 7 through 10 | 230,239,345 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2015 | (b) 2016 | (c) 2017 | (d) 2018 | (e) 2019 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2019 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2019 |
(iii) Distributable Amount for 2019 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2019 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2019: | ||||
| a From 2014....... | ||||
| b From 2015....... | ||||
| c From 2016....... | ||||
| d From 2017....... | ||||
| e From 2018....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2019 distributable amount | ||||
|
i
Carryover from 2014 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2019 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2019 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2019, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2019. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2020. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2015..... | ||||
| b Excess from 2016..... | ||||
| c Excess from 2017..... | ||||
| d Excess from 2018..... | ||||
| e Excess from 2019..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | MISCELLANEOUS - 2015 AMOUNT: $ 796. 2016 AMOUNT: $ 3,788. 2017 AMOUNT: $ 396. 2018 AMOUNT: $ 1,267. 2019 AMOUNT: $ 165. LIST RENTALS - 2015 AMOUNT: $ 9,117. 2016 AMOUNT: $ 3,691. 2017 AMOUNT: $ 2,793. 2018 AMOUNT: $ 170. 2019 AMOUNT: $ 2,201. INVENTORY - 2015 AMOUNT: $ 169,839. 2016 AMOUNT: $ 13,222. 2017 AMOUNT: $ 48,094. 2018 AMOUNT: $ 25,294. 2019 AMOUNT: $ 18,379. SPECIAL EVENTS - 2015 AMOUNT: $ 2,065,725. 2016 AMOUNT: $ 1,797,050. 2017 AMOUNT: $ 2,043,540. 2018 AMOUNT: $ 1,794,170. 2019 AMOUNT: $ 836,855. STORE SALES - 2015 AMOUNT: $ 604. 2016 AMOUNT: $ 1,250. 2017 AMOUNT: $ 2,675. 2018 AMOUNT: $ 1,859. 2019 AMOUNT: $ 701. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| IMPACT OF COVID-19 | THE EMERGENCE AND RAPID SPREAD OF COVID-19 ACROSS THE UNITED STATES IN EARLY 2020 HAS IMPACTED WORLDWIDE ECONOMIC ACTIVITY AND FINANCIAL MARKETS, HAD AN IMMEDIATE, SUBSTANTIAL AND SUSTAINED IMPACT ON AMFAR'S OPERATIONAL AND FUNDRAISING CAPACITY. WITH FUNDRAISING PERFORMANCE TIED IN LARGE PART TO AMFAR'S ABILITY TO ORCHESTRATE AND EXECUTE BENEFIT GALAS ACROSS THE U.S. AND AROUND THE WORLD, THE CORONAVIRUS LOCKDOWN AND STRICT LIMITATIONS ON INTERNATIONAL TRAVEL AND CONGREGATE EVENTS BROUGHT THIS REVENUE STREAM TO A HALT ALMOST OVERNIGHT. SINCE THE SPRING OF 2020, ALL LIVE FUNDRAISING EVENTS HAVE BEEN SUSPENDED, ALL NONESSENTIAL EXPENSES HAVE BEEN ELIMINATED, AND AMFAR HAS BEEN DEPENDENT ON ITS FINANCIAL RESERVES. THE FOUNDATION REMAINS IN A HOLDING PATTERN UNTIL SUCH TIME AS WIDESPREAD VACCINE DISTRIBUTION HAS CONTROLLED THE PANDEMIC TO THE EXTENT THAT UNFETTERED INTERNATIONAL TRAVEL AND LARGE GATHERINGS OF PEOPLE CAN RESUME. MANAGEMENT HAS CONSIDERED THE CONSEQUENCES OF COVID AND DETERMINED THAT THERE IS NO CURRENT MATERIAL UNCERTAINTY IDENTIFIED THAT WOULD AFFECT ITS ABILITY TO CONTINUE ITS MISSION TO END THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. HOWEVER, THERE IS SIGNIFICANT UNCERTAINTY AROUND THE BREADTH AND DURATION OF BUSINESS DISRUPTIONS RELATED TO COVID, AS WELL AS ITS IMPACT ON THE U.S. AND INTERNATIONAL ECONOMIES AND, AS SUCH, THE FOUNDATION IS UNABLE TO DETERMINE IF IT WILL HAVE A FUTURE MATERIAL NEGATIVE IMPACT ON ITS OPERATIONS OR FINANCIAL CONDITION. PAYCHECK PROTECTION PROGRAM LOAN ON MAY 6, 2020, AMFAR WAS GRANTED A LOAN IN AGGREGATE AMOUNT OF $1,643,364 PURSUANT TO THE SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION PROGRAM ("THE PPP") UNDER DIVISION A, TITLE 1 OF THE CARES ACT (THE "PPP LOAN"). THE PPP LOAN, WHICH WAS IN THE FORM OF A NOTE DATED MAY 1, 2020, MATURES ON MAY 6, 2022 AND BEARS INTEREST AT A RATE OF 1% PER ANNUM. THE PPP LOAN MAY BE PREPAID BY AMFAR AT ANY TIME PRIOR TO MATURITY WITH NO REPAYMENT PENALTIES. FUNDS FROM THE PPP LOAN MAY ONLY BE USED FOR CERTAIN COSTS, SUCH AS PAYROLL COSTS AND OCCUPANCY EXPENSES. THE LOAN AND ACCRUED INTEREST ARE FORGIVABLE AS LONG AS THE BORROWER USES THE LOAN PROCEEDS AS DESCRIBED IN THE CARES ACT. AMFAR USED THE ENTIRE PPP LOAN FOR QUALIFYING EXPENSES AS DESCRIBED IN THE CARES ACT AND HAVE INITIATED THE PROCESS OF THE LOAN FORGIVENESS REQUEST ACCORDING TO THE TERMS OF THE PPP LOAN. AMFAR EVALUATED ITS SEPTEMBER 30, 2020 FINANCIAL STATEMENTS FOR SUBSEQUENT EVENTS THROUGH MARCH 4, 2021, THE DATE THE FINANCIAL STATEMENTS WERE AVAILABLE TO BE ISSUED. ON FEBRUARY 19, 2021, AMFAR WAS APPROVED FOR A SECOND PPP LOAN TOTALING $1,677,930. THE PPP LOAN MATURES IN FEBRUARY 2026, AND BEAR INTEREST AT A RATE OF 1% PER ANNUM. THE PPP LOAN MAY BE PREPAID BY AMFAR AT ANY TIME PRIOR TO MATURITY WITH NO PREPAYMENT PENALTIES. FUNDS FROM THE PPP LOAN MAY ONLY BE USED FOR CERTAIN COSTS, SUCH AS PAYROLL COSTS, OCCUPANCY EXPENSES, AND CERTAIN OTHER EXPENSES. FORM 990, PART III, LINE 1 - ORGANIZATION'S MISSION THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH FOUNDATION AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. THE FOUNDATION ACCOMPLISHES THIS MISSION THROUGH: - RESEARCH TO EXPLORE SCIENTIFIC APPROACHES TO HIV PREVENTION, TREATMENT, AND POTENTIAL CURES, AND TO ENHANCE THE HEALTH AND SURVIVAL OF PEOPLE LIVING WITH HIV/AIDS; - INTERNATIONAL INITIATIVES TO FACILITATE THE DEVELOPMENT AND IMPLEMENTATION OF EFFECTIVE RESEARCH, TREATMENT, PREVENTION, AND EDUCATION STRATEGIES IN DEVELOPING COUNTRIES; - PUBLIC POLICY ANALYSIS AND THE ADVOCACY OF RATIONAL AND COMPASSIONATE POLICIES THAT PROMOTE PUBLIC HEALTH AND PROTECT THE RIGHTS OF PEOPLE THREATENED BY HIV/AIDS; - EDUCATIONAL INITIATIVES TO BUILD AWARENESS OF THE CONTINUED THREAT HIV/AIDS POSES AND TO PUBLISH UPDATES ABOUT THE LATEST MEDICAL, SCIENTIFIC, AND PREVENTION ADVANCES FOR PEOPLE LIVING WITH HIV/AIDS, HEALTHCARE PROFESSIONALS, AND THE PUBLIC. |
| FORM 990, PART III, LINE 4A: | ARCHE (AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION) FOR SEVERAL YEARS, AMFAR'S ARCHE-GT CONSORTIUM HAS BEEN DESIGNING AND FINE-TUNING THREE GENE THERAPY APPROACHES TO CURING HIV THAT COULD BE DELIVERED IN VIVODIRECTLY TO THE PATIENT. ONE APPROACH INVOLVES THE GENERATION OF CHIMERIC ANTIGEN RECEPTOR (CAR) STEM CELLS THAT ARE DESIGNED SPECIFICALLY TO KILL VIRUS-INFECTED CELLS. A SECOND IS TO SPUR LIVER CELLS TO PRODUCE HIV-SPECIFIC ANTIBODIES. THE THIRD IS TO DELIVER AN ENZYME THAT WOULD EDIT THE VIRUS OUT OF INFECTED CELLS. EACH OF THESE THREE TOOLS IS NOW READY TO BE TESTED IN COMBINATION. IN FEBRUARY 2020, DR. HILDEGARD BNING OF HANNOVER MEDICAL SCHOOL, GERMANY, WAS AWARDED $1.65 MILLION FOR A PRECLINICAL STUDY TO TEST THEIR EFFECTIVENESS. THE RESEARCHERS WILL START BY ADMINISTERING THE CAR STEM CELL TREATMENT IN THE FIRST YEAR OF THE TWO-YEAR STUDY. TREATMENT WITH THE OTHER TWO INTERVENTIONS WILL FOLLOW IN THE SECOND YEAR. AT THE END OF THIS PROOF-OF-PRINCIPLE STUDY, RESEARCHERS WILL DETERMINE THE ACTIVITY OF EACH OF THE INTERVENTIONS ALONE AND IN COMBINATION, AND THEIR EFFECT ON THE PERSISTENCE OF THE VIRUS. THIS COMPLEX GENE THERAPY STUDY WILL PROVIDE VITAL SIGNPOSTS INFORMING FURTHER CURATIVE GENE THERAPY STUDIES. MATHILDE KRIM FELLOWSHIPS IN DECEMBER 2019, AMFAR ANNOUNCED THE RECIPIENTS OF THE 2019 MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH: DR. MAOLIN LU OF YALE UNIVERSITY IN NEW HAVEN, CT, AND DR. SHAHEED ABDULHAQQ, OF OREGON HEALTH AND SCIENCE UNIVERSITY IN PORTLAND, OR. THE KRIM FELLOWSHIPS SUPPORT BRIGHT YOUNG SCIENTISTS ADVANCING INNOVATIVE SOLUTIONS TO HIV/AIDS. EACH FELLOW IS AWARDED APPROXIMATELY $150,000 OVER TWO YEARS. COVID-19 GRANTS EXPANDING ITS EFFORTS TO INCLUDE RESEARCH ON THE NOVEL CORONAVIRUS, IN APRIL 2020 AMFAR ESTABLISHED THE AMFAR FUND TO FIGHT COVID-19, ANNOUNCING ITS FIRST COVID GRANTS IN JULY. A COMMON AND OFTEN DEADLY CONSEQUENCE OF ADVANCED COVID-19 DISEASE IS ACUTE KIDNEY INJURY. CELLS IN THE KIDNEY EXPRESS THE ACE2 PROTEIN, WHICH SERVES AS A RECEPTOR FOR THE VIRUS AND MAY UNDERLIE THE KIDNEY DAMAGE. DR. MATTHIAS KRETZLER OF THE UNIVERSITY OF MICHIGAN, ANN ARBOR, WAS AWARDED $155,650 TO USE A CLEVER TECHNIQUE TO UNDERSTAND WHAT HAPPENS IN THE KIDNEY OF THOSE WITH COVID-19. BY COMPARING PATIENTS RECEIVING ANTI-INFLAMMATORY TREATMENT TO THOSE WHO WERE NOT, DR. KRETZLER AIMED TO DEVELOP A TOOL TO PREDICT WHO WOULD MOST BENEFIT FROM THIS KIND OF TREATMENT. A SECOND GRANT OF $192,000 WAS AWARDED TO DR. DANIEL KAUFMANN OF THE UNIVERSITY OF MONTREAL FOR A STUDY OF ANTIBODY RESPONSES TO COVID-19. DR. KAUFMANN WAS ABLE TO TAP INTO THE QUEBEC COVID-19 BIOBANK, ESTABLISHED AT THE BEGINNING OF THE PANDEMIC TO COLLECT BIOLOGICAL SAMPLES FROM PATIENTS ADMITTED TO THE HOSPITAL. THESE BANKED SAMPLES, COLLECTED FROM THE TIME OF ADMISSION THROUGH SEVERAL MONTHS OF FOLLOW-UP, ALLOWED DR. KAUFMANN AND HIS TEAM TO ANSWER WHY SOME PEOPLE DEVELOP ANTIBODIES AND OTHERS DO NOT, HOW WE CAN PREDICT WHETHER THOSE ANTIBODIES PROTECT AGAINST REINFECTION, AND HOW LONG THE PROTECTION WILL LAST. THE RESULTS WILL PROVIDE VALUABLE INFORMATION TO INFORM THE DESIGN OF VACCINES. PUBLISHED RESEARCH RESEARCH STUDIES MAKE THE GREATEST IMPACT ON THE HIV FIELD AND ON THE BROADER SCIENTIFIC COMMUNITY WHEN THEY ARE PUBLISHED IN SCIENTIFIC JOURNALS. IN FY2020, 80 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. EXAMPLES INCLUDE: SEEING IS BELIEVING: NUCLEAR IMAGING OF HIV PERSISTENCE A KEY BARRIER TO HIV ERADICATION IS THE PRESENCE OF LATENTLY INFECTED RESERVOIR CELLS THAT PERSIST DESPITE ART. THE ABILITY TO FIND HOST TISSUE CELLS THAT ENABLE HIV TO EVADE DISCOVERY BY ROUTINE SAMPLING MAY HELP RESEARCHERS TO IDENTIFY WHICH TISSUES ARE RESPONSIBLE FOR HIV RESURGENCE FOLLOWING TREATMENT INTERRUPTION AS PART OF A CURE INTERVENTION. DR. TIMOTHY HENRICH OF THE AMFAR INSTITUTE FOR HIV CURE RESEARCH REPORTED ON THE DEVELOPMENT OF A NEW TECHNIQUE USING PET SCANNING TO VISUALIZE THE PLACES WHERE HIV RESIDES. IN THE JOURNAL FRONTIERS IN IMMUNOLOGY, DR. HENRICH AND COLLEAGUES OUTLINED A VALUABLE TECHNIQUE USING THE ONLY EXPLORER SCANNER CURRENTLY OPERATIONAL IN THE U.S. THE MACHINE IS ABLE TO PRODUCE IMAGES THAT ARE APPROXIMATELY 40 TIMES MORE SENSITIVE THAN CURRENT TECHNOLOGY IN A FRACTION OF THE TIME. ATTACKING LATENT HIV WITH CONVERTIBLE CAR-T CELLS, A HIGHLY ADAPTABLE KILLING PLATFORM IN THE JOURNAL CELL, MEMBERS OF THE AMFAR INSTITUTE FOR HIV CURE RESEARCH REPORTED THE DEVELOPMENT OF A NEW TYPE OF CAR T CELLONE THAT CAN KEEP UP WITH HIV'S EVER MUTATING ENVELOPE. CONVERTIBLE CAR T CELLS CAN TARGET MULTIPLE STRAINS OF HIV WITHOUT THE NEED TO MANUFACTURE AS MANY DIFFERENT CAR T CELLS AS THERE ARE STRAINS. HARNESSING THE ABILITY OF THIS NEW PLATFORM TO SELECTIVELY KILL HIV-INFECTED CELLS, RESEARCHERS MAY BE ABLE TO DEVELOP MORE EFFECTIVE CURE STRATEGIES IN WHICH LATENCY-REVERSING AGENTS REACTIVATE LATENT HIV. HIV CURE SUMMIT IN NOVEMBER 2019, AMFAR HELD ITS SIXTH ANNUAL HIV CURE SUMMIT AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF), WHERE THE AMFAR INSTITUTE FOR HIV CURE RESEARCH IS BASED. LEADING AMFAR-FUNDED CURE RESEARCHERS DETAILED THEIR PROGRESS AND DISCUSSED THE SCIENTIFIC CHALLENGES THAT CONTINUE TO STAND IN THE WAY OF A CURE. DR. RACHEL RUTISHAUSER, FOR EXAMPLE, OUTLINED A PIONEERING CLINICAL TRIAL AT THE INSTITUTE THAT WILL TEST A COMBINATION APPROACH TO CURING HIV. DR. ROWENA JOHNSTON, AMFAR VICE PRESIDENT AND DIRECTOR OF RESEARCH, DISCUSSED "SOCIETIES OF RESEARCH," DISPLAYING A VISUALIZATION TOOL TO SHOW HOW IN RECENT YEARS HIV RESEARCHERS ARE COLLABORATING MORE THAN EVER BEFORE. SPEAKING WITH DR. JOHNSTON, LOREEN WILLENBERG, THE "SAN FRANCISCO PATIENT," SHARED HER INSPIRING PERSONAL STORY, FROM HER HIV DIAGNOSIS IN 1992 TO RECOGNITION BY HER DOCTORS THAT SHE WAS SOMEHOW ABLE TO MAINTAIN UNDETECTABLE VIRAL LEVELS WITHOUT EVER TAKING ART, TO BEING AN INVALUABLE PARTICIPANT IN HIV STUDIES FOR OVER A DECADE. DISCUSSING POST-TREATMENT CONTROL OF HIV, DRS. PETER HUNT OF UCSF AND MARCELLA FLORES OF AMFAR OUTLINED EFFORTS TO STUDY THE RARE INDIVIDUALS WHO ARE ABLE TO NATURALLY CONTROL THEIR VIRUS AFTER STOPPING ART. A BETTER UNDERSTANDING OF HOW THESE INDIVIDUALS ARE ABLE TO DO SO COULD HELP RESEARCHERS INDUCE POST-TREATMENT CONTROL IN OTHER PEOPLE LIVING WITH HIV. THE SUMMIT ALSO FEATURED A RANGE OF PERSPECTIVES FROM MEMBERS OF THE COMMUNITY ADVISORY BOARD FOR THE AMFAR INSTITUTE AND OTHER COMMUNITY LEADERS. |
| FORM 990, PART III, LINE 4E OTHER PROGRAM SERVICE ACCOMPLISHMENTS | AMFAR'S DEPUTY DIRECTOR OF PUBLIC POLICY BRIAN HONERMANN PRESENTED AT A VIRTUAL COMMUNITY WORKSHOP THAT FOCUSED ON THE EFFECTIVE USE OF DATA TOOLS TO DRIVE IMPACTFUL CHANGE IN THE HIV RESPONSE. AND POLICY ASSOCIATE JENNIFER SHERWOOD GAVE A SYMPOSIUM TALK ON WHETHER CURRENT APPROACHES TO COLLECTING DATA CAPTURE THE FULL IMPACT OF HIV ON WOMEN. THE CONFERENCE FEATURED MANY TALKS ON THE INTERSECTION OF HIV AND COVID-19. GREG MILLETT JOINED MERCK VICE PRESIDENT OF SOCIAL INNOVATION CARMEN VILLAR FOR A "FIRESIDE CHAT" TO DISCUSS A PAPER MILLETT CO-AUTHORED ASSESSING THE DIFFERENTIAL IMPACTS OF COVID-19 ON BLACK COMMUNITIES. MILLETT ALSO JOINED CHRIS COLLINS OF FRIENDS OF THE GLOBAL FIGHT AND OTHERS IN A SESSION TITLED HOW DID THEY DO IT? WHAT SUCCESSFUL COMMUNITIES CAN TEACH ALL OF US ABOUT MAKING DRAMATIC PROGRESS AGAINST HIV EPIDEMICS AND WHAT THIS MEANS IN THE AGE OF COVID. THE SESSION WAS A ONE-YEAR FOLLOW-UP TO A REPORT CO-AUTHORED BY AMFAR, AVAC AND FRIENDS OF THE GLOBAL FIGHT TITLED TRANSLATING PROGRESS INTO SUCCESS TO END THE AIDS EPIDEMIC. THE GMT INITIATIVE THE TWO IMPLEMENTATION SCIENCE STUDIES BEING SUPPORTED BY AMFAR'S GMT INITIATIVE CAME TO AN END IN 2019, BRINGING THE INITIATIVE TO A CLOSE. THE THREE-YEAR PROJECTS, IN MYANMAR AND THAILAND, WERE AIMED AT DETERMINING THE MOST EFFECTIVE WAYS OF ENGAGING GAY MEN, OTHER MEN WHO HAVE SEX WITH MEN (MSM), AND TRANSGENDER INDIVIDUALS (COLLECTIVELY, GMT) AT RISK OF INFECTION OR ALREADY LIVING WITH HIV. THE GOAL WAS TO HELP THOSE WHO WERE HIV-NEGATIVE STAY UNINFECTED, AND HELP HIV-POSITIVE INDIVIDUALS TO BEGIN AND REMAIN ON TREATMENT. A THIRD PROJECT, IN PERU, ENDED IN 2018. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE DRAFT FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 12C | EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. |
| FORM 990, PART VI, SECTION B, LINE 15 | AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. AMFAR'S LAST INDEPENDENT COMPENSATION STUDY WAS CONDUCTED IN NOVEMBER OF 2019 TO ENSURE THAT THE PRESIDENT & CEO'S COMPENSATION IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. |
| FORM 990, PART VI, SECTION C, LINE 19 | AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED, WILL BE PROVIDED AT MANAGEMENT'S DISCRETION. |
| PART IX, LINES 1 & 3 | THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F. |
| Software ID: | |
| Software Version: |